Australia's most trusted
source of pharma news
Saturday, 24 May 2025
Posted 23 May 2025 AM
Medtronic has announced it will spin off its diabetes unit to create a separate standalone company in an effort to simplify its portfolio in high margin growth markets.
The new diabetes business will kick off with a US$2.8 billion portfolio and aims to distinguish itself as "the only company to commercialise a complete ecosystem to address intensive insulin management."
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.